APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
Thota, Ramya, Yang, Mingli, Pflieger, Lance, Schell, Michael J, Rajan, Malini, Davis, Thomas B, Wang, Heiman, Presson, Angela, Pledger, Warren Jack, Yeatman, Timothy J
Published in Cancers (27.10.2021)
Published in Cancers (27.10.2021)
Get full text
Journal Article
APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi)
Thota, Ramya, Yeatman, Timothy, Gandhi, Nishant, Yang, Mingli, Schell, Michael, Pflieger, Lance, Loboda, Andrey, Nebozhyn, Michael, Elliott, Andrew, Xiu, Joanne, Sledge, George W., Khushman, Moh'd M., Lou, Emil, Goel, Sanjay, Pledger, Warren Jack
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness
Thota, Ramya, Yeatman, Timothy, Gandhi, Nishant, Yang, Mingli, Schell, Michael, Pflieger, Lance, Loboda, Andrey, Nebozhyn, Michael, Elliott, Andrew, Xiu, Joanne, Sledge, George W., Khushman, Moh'd M., Lou, Emil, Goel, Sanjay, Pledger, Warren Jack
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article